A GenMeds GuideCardiovascular PreventionUpdated July 2026
The best way to lower LDL cholesterol and prevent heart disease
Of all the things that cause heart attacks, heart failure, and stroke, LDL cholesterol is the one you can do the most about. Decades of research point to one rule: the lower your LDL, and the longer you keep it there, the better.
Authors
Braidwell AI Alex Karnal Nick Myerberg Dr. Josh Sims Dr. Robert Stoekenbroek Dr. Andrew Badley Dr. Nihar Desai
About this document
A living guide, updated in as close to real-time as we and our Braidwell AI system can, reviewing every FDA-approved LDL-lowering medicine and the science behind them, written for everyone.
Reading time
~20 minutes
Last substantive review
July 17, 2026
§01What we recommend
What we tell our friends and family
We tell our friends and family to start treatment early — before damage to the arteries has begun. There is no level of LDL that is "too low." Your cells make all the cholesterol they need on their own. So we say start with the medicines that bring LDL down the most, with the fewest side effects. The goal is to get LDL under 50 mg/dL. This is the level we are naturally born with, that hunter-gatherer populations maintain throughout life, and the range where atherosclerosis largely stalls instead of actively progressing.
PCSK9 inhibitors are a class that now includes five approved medicines: evolocumab (Repatha), alirocumab (Praluent), lerodalcibep (Lerochol),inclisiran (Leqvio), and enlicitide (Lipfendra). We prefer to start treatment with these. They produce the largest LDL reductions of any approved medicines. In clinical trials involving tens of thousands of patients, rates of side effects were comparable to placebo.
Recently, the first oral PCSK9 inhibitor was approved. Statins are oral medications that have been on the market for many years. But the statin FDA labels warn of muscle damage, liver enzyme abnormalities, and increases in blood sugar that can lead to new-onset diabetes. In real-world studies, roughly 10-25% of statin users report muscle symptoms.
The relationship between LDL and heart disease is continuous — there is no biological threshold below which the benefit stops. In a prespecified analysis of the trial, patients who achieved the lowest LDL levels continued to see fewer heart attacks and strokes, with no increase in side effects, all the way down well below 20 mg/dL. So once a PCSK9 inhibitor has done the heavy lifting, it may be worth adding a second and third medicine on top — depending on how much further you want to push your risk down.
The medicines in this guide are FDA-approved. They work. They have different strengths and trade-offs. The right choice depends on your numbers, your preferences, and your ability to afford them — not on which drug a guideline committee ranked first many years ago.
§02The bottom line
The benefit compounds with duration. Start earlier. Go lower
Heart disease is driven by cumulative exposure to LDL particles over time — what researchers call "LDL-years." This makes intuitive sense. LDL particles carry most of the cholesterol — a fatty substance — in our blood. LDL particles are small and can penetrate the arterial wall and accumulate, leading to the formation of atherosclerotic plaques. The more particles and the longer arteries are exposed, the more accumulation, the more plaque, and the higher the risk of heart attacks and strokes. Every year of elevated LDL-C adds to a running total of arterial damage. Conversely, the earlier and lower you go, the more you prevent. There is no threshold below which benefit stops.
People born with naturally low LDL, because of genetic variants in PCSK9 or other genes, have 50–90% less coronary heart disease than the general population, despite only modestly lower LDL levels (15–40 mg/dL lower). A 5-year statin trial, by contrast, produces roughly a 22% risk reduction despite achieving a similar or even larger absolute LDL-C drop.
The difference is time. The genetic experiment delivers decades of lower exposure starting from birth; a statin trial delivers a few years starting in middle age. The implication: to maximize the impact of LDL lowering, one has to start earlier in life, before significant damage to the arterial wall has occurred.
Interactive · Lower & longer
How much risk you avoid depends on how low you go, and for how long.
Based on the CTT relationship of ~22% relative risk reduction per ~39 mg/dL of LDL-C lowering, scaled to treatment duration per the Ference / EAS Consensus formula.
Relative risk reduction in major cardiovascular events72.6%
LDL-C drop
105 mg/dL · 66%
Time compounds · Ference 2017
Time matters more than intensity
Risk reduction per 1 mmol/L of sustained LDL-C lowering grows with the number of years on treatment.
This is the most important insight in cardiovascular prevention: the benefit compounds with duration. Starting earlier matters. Going lower matters. Lower for longer is better; lowest for longest is best.
§03Why this works
What the science actually shows
Genetics and direct visualization converge on the same picture.
People born with less PCSK9 almost never get heart disease
In 2006, researchers found people carrying natural loss-of-function mutations in the PCSK9 gene, the same target that PCSK9 inhibiting medicines hit with a drug. These people have had lower LDL since birth, not because of any medication, but because of their DNA.
Cohen et al., 2006 — coronary protection by lifelong PCSK9 reductionn ≈ 12,000
Group
How much lower their LDL
Less coronary heart disease
Black participants with nonsense mutations
28% lower (~40 mg/dL less)
88% less
White participants with missense mutation
15% lower (~21 mg/dL less)
47% less
Notice the asymmetry: a modest LDL difference (15–28%) produced an outsized reduction in disease (47–88%). That is the power of lifelong exposure. A statin trial achieves a larger percentage LDL drop over 5 years and delivers ~22% risk reduction — still worthwhile, but far less than what decades of lower exposure produce. The implication: start as early as makes sense for your risk, and stay on treatment.
The disease physically gets smaller when treated
You can see the disease getting smaller on a screen, reversing its course. The people who went lowest in their LDL-C had the most regression. There was no level at which the benefit plateaued. This is what "lower is better" looks like inside an artery.
You can watch the disease shrink.
GLAGOV · IVUS · N=846
In the trial, researchers used intravascular ultrasound — a tiny camera inside the coronary arteries — to directly measure atherosclerotic plaque in 846 patients already on statins. Half received evolocumab (Repatha) on top. The people who went lowest over 76 weeks had the most regression.
Statin aloneLDL 93 mg/dL
47% saw plaque regression
Statin + evolocumabLDL 37 mg/dL
64% saw plaque regression
47%
Patients with plaque regression with statin alone
64%
Patients with plaque regression with statin + evolocumab
-56 mg/dL
Achieved LDL-C difference between arms
The trial (n=300) replicated this finding with alirocumab post-acute heart attack: percent atheroma volume regressed by -2.13% vs -0.92% with placebo (p<0.001). Different drug, different trial, same geometry — the disease gets smaller when LDL goes lower.
§05What changed in 2025
The two largest barriers to PCSK9 access just fell away
The FDA expanded evolocumab's (Repatha) label based on data from the trial: in 12,257 patients without prior heart attack or stroke, evolocumab reduced 3-point MACE by 25% (HR 0.75, p<0.0001) and heart attack alone by 36% over 4.6 years. The new label covers adults at increased risk for cardiovascular events — no prior event required, no step therapy needed. Alirocumab (Praluent) followed with a parallel label expansion.
Separately, Amgen launched AmgenNow, a direct pricing program that brought the cash price of Repatha down to $239/month at over 70,000 pharmacies — roughly 60% below the previous list price and less than many branded oral therapies.
Lerodalcibep (Lerochol), approved by the FDA in December 2025, brought the floor lower still. At $199/month cash with monthly rather than biweekly dosing and room-temperature storage, it is both the least expensive PCSK9 inhibitor available and the most logistically forgiving.
Together, these changes removed the two largest barriers to PCSK9 inhibitor access: the indication restriction and the price.
25%
VESALIUS-CV reduction in 3-point MACE in patients without prior heart attack or stroke
36%
VESALIUS-CV reduction in heart attack alone over 4.6 years
$239/mo
Cash price of Repatha at 70,000+ pharmacies via AmgenNow
$199/mo
Cash price of Lerochol, the lowest price for any PCSK9 inhibitor
§06What to measure
Not every test matters equally. We rank by whether the result changes what you do.
A note on family history
A first-degree relative with a documented heart attack, stroke, or cardiovascular death before age 55 in men or 65 in women raises ASCVD risk by approximately 50% above what your measured biomarkers and risk factors capture. Part of the excess risk may be mediated through Lp(a), which is one reason to measure it.
Essential — measure these
Test
Why it matters
How often
Target
LDL-C
The primary driver of atherosclerotic cardiovascular disease. This is the number to track and lower.
Baseline + 8-12 weeks after any change in medication. At least yearly thereafter.
Lower is better. No floor. We recommend targeting 50 mg/dL to halt plaque build-up in arteries for most people, and potentially lower in people with established plaque.
Lp(a)
Genetically determined, independent risk factor. Lp(a) particles are effectively LDL particles with added characteristics that make them even more dangerous. Elevated in ~20% of people. Does not change with lifestyle or most drugs. Measure once. Usually not part of a standard lipid panel, so this needs to be requested separately.
Once
<50 nmol/L or <20-25 mg/dL. If elevated, it strengthens the case for aggressive LDL-C lowering. No approved Lp(a)-lowering therapy yet.
HbA1c
Diabetes is an ASCVD risk equivalent. Metabolic health and insulin resistance directly affect cardiovascular risk. HbA1c is a measure of your blood glucose over a 2 to 3 month period. It is more stable than a direct blood glucose measurement, which varies greatly during the day and between days.
Annually
<5.7% normal; ≥6.5% = diabetes.
Blood Pressure
Independent and synergistic. Hypertension significantly increases ASCVD risk at any LDL level.
Every visit
120/80 mmHg for most adults.
Optional — measure if your doctor recommends
Test
Why it matters
When to consider
Target / notes
ApoB
Counts every atherogenic particle directly — more precise than LDL-C, especially when triglycerides are elevated or LDL-C and clinical risk seem discordant.
Diabetes, elevated triglycerides, or discordant LDL-C and clinical risk
<45 mg/dL
hsCRP
Measures inflammatory risk, a second causal axis of heart disease beyond cholesterol. CANTOS proved that inflammation alone drives cardiovascular events.
Baseline; after treatment
<2.0 mg/L conventional; <1.0 mg/L ideal.
CAC Score
Direct visualization of coronary plaque burden. A score of 0 in otherwise low-risk people is reassuring. >100 reclassifies risk upward.
Once, when risk classification is uncertain
0 is optimal; >100 = treat aggressively.
§07General principles
Four principles that apply to every LDL-C lowering therapy
Before choosing a specific therapy, understand the principles that apply to all of them.
01
Lower for longer is better. Lowest for longest is best
Every ~39 mg/dL of LDL-C reduction lowers major cardiovascular events by ~22% over 5 years, starting from any baseline. This relationship is log-linear and does not plateau. People who achieve LDL-C below 20 mg/dL in trials continue to show benefit with no excess harm.
The benefit compounds over time. People with genetically low LDL from birth get 3–4x more risk reduction per unit of LDL lowered than people who start in their 50s because they have had decades more exposure to the benefit. A lipid lowering treatment started at 35 and continued through 75 produces benefits closer to lifelong genetic protection than to a 5-year clinical trial.
02
The mechanism does not matter
Statins, ezetimibe, PCSK9 inhibitors, and bile acid sequestrants produce the same cardiovascular benefit for each given LDL-C reduction. The only thing to focus on is the magnitude of the LDL-C reduction. PCSK9s offer the greatest LDL-C reduction and therefore the greatest cardiovascular benefit over time, generally with fewer side effects than statins.
Concordance principle · Ference 2015 & 2016
It does not matter how you lower LDL. Only that you do
A landmark Mendelian randomization study compared the genetic equivalents of three drug mechanisms. Per 10 mg/dL of LDL-C reduction, the benefit is statistically indistinguishable.
StatinsHMGCR19%
EzetimibeNPC1L118%
PCSK9 inhibitorsPCSK919%
Every mechanism that reduces the number of LDL particles in your blood produces the same proportional benefit. There is no special sauce — just fewer particles, for longer. This means the choice between therapies should be driven by your preferences (cost, convenience, side effects), not by any belief that one mechanism is biologically superior to another.
Choose the option that fits your life — cost, convenience, side effects, dosing — not the one with a particular mechanism.
03
Lifestyle runs in parallel, not as a prerequisite
Diet, exercise, sleep, weight management, and smoking cessation are good for everyone, regardless of medication. They improve cardiovascular risk through multiple pathways beyond LDL-C (blood pressure, insulin sensitivity, inflammation, endothelial function). But lifestyle alone typically reduces LDL-C by only 5–15%, which is rarely sufficient for people at meaningful risk.
Do not treat lifestyle as Step 1 and medication as Step 2. They are concurrent. A person who needs an LDL-C reduction of 50% will not get there with diet alone, and delaying medication while "trying lifestyle first" costs time — and time is the variable that matters most.
04
There is no LDL level that is too low
This is the most important safety principle in the guide. The concern is understandable: if cholesterol is essential for cell membranes and hormones, won't low levels cause harm?
No. Here is why:
Every cell in your body makes all the cholesterol it needs. Cholesterol is synthesized de novo via the mevalonate pathway in every nucleated cell. The brain produces approximately 95% of its cholesterol locally, behind the blood-brain barrier. Circulating LDL does not cross this barrier in meaningful amounts.
Steroid hormones do not depend on LDL. Steroidogenic tissues primarily use HDL-delivered cholesterol via the SR-BI receptor and their own de novo synthesis. The evolocumab substudy directly measured cortisol, testosterone, and estradiol in people achieving LDL below 15 mg/dL. There was zero correlation between LDL-C change and any hormone level.
The clinical data confirm the safety of achieving very low LDL levels at scale:
Cognition: The study performed serial formal neuropsychological testing in patients on evolocumab whose LDL-C reached a median of ~30 mg/dL, with many below 20 mg/dL. No differences appeared on any cognitive domain. A broader analysis of 22,655 FOURIER participants found no cognitive decline even in the 2,338 people who reached LDL-C below 20 mg/dL.
Hemorrhagic stroke: In , among 730 people who transiently reached LDL-C below 15 mg/dL: zero hemorrhagic strokes. A meta-analysis of 39 PCSK9 inhibitor RCTs (66,478 patients) found no hemorrhagic stroke excess.
New-onset diabetes: In , HR was 1.05 (95% CI 0.94–1.17). In , HR was 1.00 (0.89–1.11). No statistically significant increase appeared in either trial.
Cancer: CTT Collaboration meta-analysis of 170,000+ people: RR 1.00 (95% CI 0.96–1.04) — no relationship. Observational associations between low LDL and cancer are reverse causation.
People with lifelong very low LDL are healthy. PCSK9 loss-of-function carriers show 47–88% less coronary disease, normal neurocognition, normal adrenal function, and normal fertility. There is no clinical syndrome associated with having too-low LDL.
§08Available medicines
Every LDL-C-lowering therapy has a place. The right choice depends on you.
Every approved LDL-C-lowering therapy has a place. The right choice depends on what matters to you: how much LDL-C reduction you need, whether you prefer a pill or an injection, how often you want to deal with it, what side effects you are willing to accept, and what you can afford. We describe each option objectively along these dimensions.
Largest LDL-C reductions & cleanest safety
PCSK9-based therapies
The strongest LDL-C lowering class in the guide. Various therapies available within this class.
Small recombinant fusion protein (~77 kDa) consisting of a PCSK9-binding adnectin fused to human serum albumin. It binds and neutralizes PCSK9, preventing degradation of LDL receptors — the same mechanism as Repatha and Praluent, but in a different molecular format, not a monoclonal antibody.
Trials & outcomes
showed ~56-62% LDL-C reduction, ApoB reductions of ~36-45%, Lp(a) reductions of ~25-33%, and sustained lowering over 2+ years in the open-label extension with no attenuation.
Safety
Well-tolerated. Injection site reactions such as pain and redness in 12-18% are the most common adverse event — slightly higher than for PCSK9 antibodies, likely due to the larger injection volume.
Monoclonal antibody that blocks PCSK9 protein, preventing it from degrading LDL receptors on liver cells. More LDL receptors on the liver surface means more LDL cleared from the blood. LDL-C reduction is ~60% as monotherapy — materially more than what most statins achieve.
Trials & outcomes
Cardiovascular outcomes are established. showed a 15% reduction in the primary composite endpoint and a 20% reduction in CV death, heart attack, or stroke. extended benefit into patients without prior heart attack or stroke, showing a 25% reduction in the primary composite endpoint and a 36% reduction in heart attack, supporting the 2025 label expansion. PCSK9 antibodies also lower Lp(a) by ~24–27%; in ODYSSEY, mediation analyses suggested that Lp(a) reduction contributed independently to benefit.
Safety
Comparable to placebo in . Mild injection-site reactions around 2%. No myopathy, hepatotoxicity, or new-onset diabetes. Cognitive safety has been formally tested at LDL <20 mg/dL and cleared. Steroid hormones are unaffected.
An oral macrocyclic peptide that blocks the PCSK9 protein - the same target as the injectable PCSK9 antibodies (Repatha, Praluent) - preventing PCSK9 from degrading LDL receptors on liver cells. More LDL receptors on the liver surface means more LDL cleared from the blood. It is the first PCSK9 inhibitor to achieve antibody-level LDL lowering in a once-daily pill rather than an injection.
Trials & outcomes
The Phase 3 CORALreef program enrolled more than 19,000 participants. In , enlicitide reduced LDL-C by ~56% versus placebo at 24 weeks, and also had meaningful reductions in non-HDL-C, ApoB, and Lp(a), similar to the monoclonal antibodies. A dedicated cardiovascular outcomes trial, , is still ongoing - so, unlike Repatha and Praluent, hard cardiovascular-event data are not yet available. Because the LDL-C lowering is similar to the antibodies and Lipfendra works through the identical mechanism, it is highly unlikely that the cardiovascular benefit would be any different than the monoclonal antibodies (although trial design differences such as duration play a big role in the ultimate number produced in the trial).
Safety
In the Phase 3 program, adverse events were comparable to placebo with low discontinuation rates. As an oral peptide it does not carry the injection-site reactions seen with the injectables.
Same target and mechanism as evolocumab: blocks PCSK9 protein, preserves LDL receptors, clears more LDL from the blood. LDL-C reduction is ~60% as monotherapy.
Trials & outcomes
showed 15% reduction in the primary composite endpoint after acute coronary syndrome. PCSK9 antibodies reduce Lp(a) by ~24-27%, and Lp(a) lowering contributed to event reduction independently of LDL-C lowering in ODYSSEY mediation analysis.
Small interfering RNA (siRNA) that silences PCSK9 production in the liver. Same target as Repatha/Praluent, but works at the gene expression level rather than the protein level. LDL-C reduction is ~50%.
Trials & outcomes
Three Phase 3 trials (~3,660 people with ASCVD, ASCVD risk equivalent, or familial hypercholesterolemia) showed LDL-C reductions of ~50% (up to 52%), and long-term extension data (ORION-8) show the effect persists for up to ~6 years.
Safety
Injection site reactions such as pain and redness in ~8% of people. The available safety data from Phase 3 trials (ORION-9, -10, -11) show a generally clean profile.
Low cost · broad evidence
Statins
Daily oral medicines with the deepest outcomes evidence and the lowest cash prices.
AtorvastatinStatinLDL-C reduction35-55%
FormatOral tabletDosingDailyPrice$4-15/mo
Mechanism
Inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. The liver compensates by upregulating LDL receptors, pulling more LDL from the blood. LDL-C reduction is 35-55% depending on drug and dose; high-intensity regimens (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) achieve the upper end.
Trials & outcomes
The deepest evidence base of any drug class in medicine. CTT meta-analyses across 170,000+ people and 26 trials: 22% reduction in major vascular events per 1.0 mmol/L (~39 mg/dL) LDL-C reduction, including ~10% all-cause mortality reduction. As of May 2026, statins remain the only LDL-lowering class to have demonstrated a statistically significant all-cause mortality benefit in randomized trials — likely reflecting shorter trial durations for newer agents rather than a biological difference, but still worth noting.
Safety
Muscle symptoms are a common reason people stop. In observational studies, statin-associated muscle symptoms are reported by roughly 10-25%. Based on trials where people do not know whether they are taking a statin or placebo, much of it is not caused by the statin. Genuine statin myopathy is uncommon, affecting roughly 1 per 1,000 to 1 per 10,000 people per year and is dose dependent. Rhabdomyolysis is rarer still: 1 per 10,000 person-years. New-onset diabetes: odds ratio 1.09 (95% CI 1.02-1.17), equivalent to roughly 1 additional case per 255 patients treated for 4 years; risk is greater with higher intensity therapy and most new diagnoses occur in people whose blood glucose is already near the diabetes threshold.
RosuvastatinStatinLDL-C reduction35-55%
FormatOral tabletDosingDailyPrice$4-15/mo
Mechanism
Same class as atorvastatin: inhibits HMG-CoA reductase, causing the liver to upregulate LDL receptors and pull more LDL from the blood. Slightly more potent at the high end of the dose range.
Trials & outcomes
The deepest evidence base of any drug class in medicine. CTT meta-analyses across 170,000+ people and 26 trials: 22% reduction in major vascular events per 1.0 mmol/L (~39 mg/dL) LDL-C reduction, including ~10% all-cause mortality reduction. demonstrated benefit in people with elevated hsCRP. As of May 2026, statins remain the only LDL-lowering class to have demonstrated a statistically significant all-cause mortality benefit in randomized trials — likely reflecting shorter trial durations for newer agents rather than a biological difference, but still worth noting.
Safety
Same class considerations as atorvastatin: reported muscle symptoms, rare true myopathy, diabetes risk concentrated near the diabetes threshold, hepatic monitoring, and rare rhabdomyolysis.
Add-ons and alternatives
Other LDL-lowering medicines
Oral add-ons, statin alternatives, and emerging non-statin pathways that lower LDL.
Blocks intestinal cholesterol absorption via the NPC1L1 transporter — a completely different pathway from statins or PCSK9 inhibitors.
Trials & outcomes
LDL-C reduction is ~18-20% as monotherapy, or as an add-on to any other therapy. Ference Mendelian randomization data confirm that each 10 mg/dL of LDL-C reduction from ezetimibe produces the same cardiovascular benefit as from a statin or PCSK9 inhibitor.
Safety
Well-tolerated. Minimal side effects, mostly mild GI symptoms.
Inhibits ATP citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Acts only in the liver because it is a prodrug activated by a liver-specific enzyme, which is why it does not cause the muscle symptoms seen with statins.
Trials & outcomes
LDL-C reduction is ~18% as monotherapy. When combined with ezetimibe as Nexlizet, ~38%. showed 13% reduction in the 4-point MACE primary composite — a real but modest effect consistent with the modest LDL-C reduction.
Safety
showed elevated uric acid 10.9% vs 5.6%, gout 3.1% vs 2.1%, tendon rupture as an FDA labeled Warning and Precaution (0.5% vs. 0%), gallstones 2.2% vs. 1.2%, and hepatic enzyme elevations 4.5% vs 3.0%. No excess myalgia — this is its one clear advantage over statins.
Prices reflect US cash/self-pay rates as of early 2026. Verify with manufacturer programs, GoodRx and your pharmacy.
§10How to get PCSK9 inhibitors
Access has improved dramatically. Here's the current landscape
Statins and ezetimibe are cheap, generic and available at any pharmacy. PCSK9 inhibitors are newer and historically harder to obtain, so this section focuses on them.
01 · Cash pay
No insurance needed
Repatha$239/mo
AmgenNow at 70,000+ pharmacies via GoodRx. Available regardless of insurance status, including Medicare.
Lerochol$199/mo
Lerodalcibep (Lerochol), approved by the FDA in December 2025, brought the floor lower still. At $199/month cash, it is the least expensive PCSK9 inhibitor available.
02 · Through insurance
Prior authorization
Coverage
Most plans still require prior authorization. Approval rates are rising after the VESALIUS-CV label expansion.
Appeals
Document LDL-C level, risk factors, and prior therapies. Appeals often succeed; persistence matters.
What to ask your doctor
"I'd like my LDL-C and Lp(a) measured."
"Based on my risk, what are my options for lowering LDL-C?"
"Can we look into PCSK9 inhibitor access, including cash pricing?"
"What does my insurance require for coverage, and is there a patient-assistance program?"
§11What we still don't know
The honest open questions
?
Anti-inflammatory therapy beyond colchicine
CANTOS proved the axis. Colchicine is approved but adoption is low and the drug-drug interaction profile limits use. Targeted IL-6 and IL-1beta agents may offer cleaner benefit-risk profiles.
?
Lp(a) lowering
Pelacarsen and olpasiran are in Phase 3. We do not yet know whether lowering Lp(a) reduces cardiovascular events.
§12Sources
Every claim, grounded
We cite throughout. Hover any n in the text for a one-line summary; click to highlight the entry below. Source links open the underlying paper when available.
[1]
FOURIER
Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
Bohula EA, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine. 2026;394(2):117-127. doi:10.1056/NEJMoa2514428
Schwartz GG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174
Cholesterol Treatment Trialists’ (CTT) Collaboration, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5
Nissen SE, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024
Wood FA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. New England Journal of Medicine. 2020;383(22):2182-2184. doi:10.1056/NEJMc2031173
Herrett E, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. doi:10.1136/bmj.n135
Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
Cohen JC, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. The New England Journal of Medicine. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
Ference BA, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine. 2016;375(22):2144-2153. doi:10.1056/NEJMoa1604304
Ference BA, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. Journal of the American College of Cardiology. 2015;65(15):1552-1561. doi:10.1016/j.jacc.2015.02.020
Nicholls SJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
Giugliano RP, et al. Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine. 2017;377(7):633-643. doi:10.1056/NEJMoa1701131
Gencer B, et al. Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology. 2020;75(18):2283-2293. doi:10.1016/j.jacc.2020.03.039
Schwartz GG, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European Heart Journal. 2023:ehad144. doi:10.1093/eurheartj/ehad144
Mefford MT, et al. PCSK9 variants, LDL-cholesterol, and neurocognitive impairment: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Circulation. 2018;137(12):1260-1269. doi:10.1161/CIRCULATIONAHA.117.029785
Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
Ridker PM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. doi:10.1016/S0140-6736(17)32814-3
Blom DJ, et al. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. Circulation Research. 2015;117(8):731-741. doi:10.1161/CIRCRESAHA.115.307071
Benn M, et al. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. Journal of the National Cancer Institute. 2011;103(6):508-519. doi:10.1093/jnci/djr008
Nidorf SM, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372
Klug EQ, et al. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiology. 2024;9(9):800-807. doi:10.1001/jamacardio.2024.1659
Kereiakes D, et al. Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD). Atherosclerosis. 2024;395. doi:10.1016/j.atherosclerosis.2024.118513
Lloyd-Jones DM, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204-2211. doi:10.1001/jama.291.18.2204
Bachmann JM, et al. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation. 2012;125(25):3092-3098. doi:10.1161/CIRCULATIONAHA.111.065490
Guedeney P, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal. 2022;43(7):e17-e25. doi:10.1093/eurheartj/ehz430
Fritz J, et al. Metabolic Mediators of the Effects of Family History and Genetic Risk Score on Coronary Heart Disease—Findings From the Malmö Diet and Cancer Study. Journal of the American Heart Association. 2017;6(3):e005254. doi:10.1161/JAHA.116.005254
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi:10.1016/S0140-6736(18)32261-X
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
Räber L, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
Bruckert E, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovascular Drugs and Therapy. 2005;19(6):403-414. doi:10.1007/s10557-005-5686-z
Illingworth DR, et al. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. The Journal of Clinical Endocrinology and Metabolism. 1982;54(1):27-33. doi:10.1210/jcem-54-1-27
Cariou B, et al. Preserved adrenal function in fully PCSK9-deficient subject. International Journal of Cardiology. 2014;176(2):499-500. doi:10.1016/j.ijcard.2014.07.057
Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. doi:10.1016/S0140-6736(09)61965-6
Preiss D, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-2564. doi:10.1001/jama.2011.860
Ballantyne CM, et al. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. Journal of the American College of Cardiology. 2023;81(16):1553-1564. doi:10.1016/j.jacc.2023.02.018
Amgen press release. — AmgenNow direct pricing program for Repatha (evolocumab). October 2025.
[52]
Stroes 2015
Stroes ES, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012-1022. doi:10.1093/eurheartj/ehv043
Graham DJ, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. doi:10.1001/jama.292.21.2585
Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819
Merck & Co., Inc.. Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia. Merck & Co., Inc.. 2026.
U.S. National Library of Medicine. Cardiovascular Outcomes Study of Enlicitide Decanoate (MK-0616) in Participants at High Cardiovascular Risk (CORALreef Outcomes). U.S. National Library of Medicine (ClinicalTrials.gov). 2026.
Randomized Controlled Trials — Reviewed FOURIER, VESALIUS-CV, ODYSSEY OUTCOMES, IMPROVE-IT, CLEAR Outcomes, CANTOS, LoDoCo2, COLCOT, SAMSON, StatinWISE, GLAGOV, PACMAN-AMI, EBBINGHAUS, DESCARTES, the LIBerate Phase 3 program, and GLP-1 RA cardiovascular outcomes trials. Prioritized large, well-powered, placebo-controlled trials with hard cardiovascular endpoints. Genetic and Epidemiologic Evidence — Integrated Mendelian randomization data (concordance principle, LDL-years framework), PCSK9 loss-of-function cohorts, and the EAS consensus statement on LDL causality. Safety at Very Low LDL — Reviewed cognitive, hormonal, hemorrhagic stroke, diabetes, and cancer safety data, including genetic evidence from PCSK9 loss-of-function carriers. Pricing — Confirmed current US cash prices through GoodRx, manufacturer direct programs, and pharmacy benefit databases as of early 2026.